Latest Regulatory News

Mamba Exploration has secured a 70% stake in the Meeka East Gold Project following a $2 million placement and completed a major soil sampling program, setting the stage for a maiden drilling campaign pending assay results and approvals.

Trek Metals has wrapped up the second tranche of its $15 million placement, issuing nearly 9.7 million shares to directors at 15 cents each after shareholder approval. The move bolsters the company’s capital ahead of its drilling campaign at the Kuro manganese prospect.

Temas Resources is tapping the Canadian market with a $1.5 million flow-through share placement aimed at advancing its titanium projects in Quebec. The raise supports exploration expenses tied to its proprietary processing technology and resource development.

Clara Resources has compiled a comprehensive digital geochemistry database from 1980s exploration data, revealing a large-scale gold system at its Mareeba Gold Project in Queensland and setting the stage for maiden drilling in H2 2026.

PYC Therapeutics has secured Safety Review Committee approval to escalate dosing of its investigational drug PYC-001 for Autosomal Dominant Optic Atrophy from single to multiple doses, marking a key step in its clinical development.

Ovanti Limited has raised $5.27 million through a discounted placement, aiming to accelerate its global Buy Now Pay Later platform and Super App development with AI integration and merchant expansion.

Marquee Resources (ASX:MQR) has secured a non-exclusive R&D patent licence with Oak Ridge National Laboratory, granting access to NEAREST technology tailored for clay-rich rare earth deposits like Redlings in WA. This partnership could reshape processing efficiency and environmental impact for Marquee’s significant inferred resource.

ReNerve has moved its NervAlign Nerve Guide Matrix into stage 3 of commercial development, a key step toward FDA submission and eventual market entry. This progress supports the company’s ambition to provide surgeons with an alternative to donor nerves for repairing severe peripheral nerve injuries.

Australian Unity Office Fund has secured Foreign Investment Review Board approval for the $40 million sale of its Brisbane office tower, setting the stage for a pivotal unitholder meeting to approve the sale, delisting, and wind-up of the fund.

Immutep Limited has won FDA Orphan Drug Designation for its immunotherapy eftilagimod alfa in treating soft tissue sarcoma, opening regulatory incentives and potential market exclusivity. This follows encouraging Phase II data despite recent Phase III trial setbacks.

Mesoblast has acquired exclusive rights to a patented chimeric antigen receptor platform designed to enhance the targeting and potency of its mesenchymal stromal cell therapies, aiming to expand treatment options for inflammatory and autoimmune diseases.

Riversgold Limited has reported standout assay results from 31 drill holes at its Northern Zone Gold Project, including a spectacular 71 g/t gold intercept. The campaign expands the shallow gold mineralisation footprint, supporting imminent mining lease conversion and a funding agreement with MEGA Resources.